Conmed Corp
NYSE:CNMD
Conmed Corp
Cash from Financing Activities
Conmed Corp
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Conmed Corp
NYSE:CNMD
|
Cash from Financing Activities
-$110.4m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
-$1.6B
|
CAGR 3-Years
-425%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$7.1B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is Conmed Corp's Cash from Financing Activities?
Cash from Financing Activities
-110.4m
USD
Based on the financial report for Dec 31, 2023, Conmed Corp's Cash from Financing Activities amounts to -110.4m USD.
What is Conmed Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-13%
The average annual Cash from Financing Activities growth rates for Conmed Corp have been -28% over the past three years , -9% over the past five years , and -13% over the past ten years .